Akme Fintrade Enters Life Insurance Distribution Through Axis Max Life

Udaipur: Akme Fintrade (India) Limited (AFIL) today announced that ithas entered into a Corporate Agency Agreement with Axis Max Life Insurance Limited to solicit and procure life insurance products on behalf of Axis Max Life.Through this strategic partnership, Akme Fintrade will leverage its nationwide customer base to tap cross-selling opportunities in the life insurance segment, thereby expanding its non-interest income portfolio. The initiative is expected to contribute to incremental operating income and support improvement in the Company’s overall profitability, while strengthening the diversity and resilience of its revenue streams.

Elaborating on the development, Mr. Akash Jain, CEO, Akme Fintrade, said, “Our partnership with Axis Max Life is closely aligned with our long-term strategy of building diversified and sustainable revenue streams, while deepening customer relationships through a broader and more integrated suite of financial solutions. Life insurance represents a natural extension of our existing offerings, and we believe this collaboration will create enduring value for all stakeholders. We see strong potential in cross-selling life insurance products to both existing and new customers, further strengthening the overall value proposition we deliver.”

Strengthening Capital Through NCD Issuances :

In parallel development, Akme Fintrade has continued to strengthen its capital base through timely fund-raising in the debt market. In December 2025 and January 2026, the Company successfully raised Rs 50.00 crore through the issuance of Non-Convertible Debentures (NCDs) at a coupon rate of 11.50%.

In addition, during the financial year 2025–26, the Company has raised an aggregate amount of Rs 180.00 crore through multiple tranches of NCDs via the private placement route.The proceeds from these issuances are being utilised to support business growth, improve asset-liability maturity and further enhance liquidity and capital adequacy.